Ovid Therapeutics Inc.
OVIDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Ovid Therapeutics Inc. (OVID) is listed under Biotechnology. The company carries a $546.8M market cap, placing it firmly in the small-cap category. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Market Cap
$546.8M
Beta
0.25
P/E (TTM)
—
P/E (Fwd)
-7.08
EPS (TTM)
$-0.21
EPS (Fwd)
$-0.40
ROE
-26.0%
ROA
-23.5%
Cash
$117.2M
Total Debt
$12.7M
Free CF
-$33.1M
52W Change
125.8%
Annual Financials
Cash vs Debt
Where OVID stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, OVID finished 14.35% above its 150-day moving average ($2.37) and 24.31% above its 200-day moving average ($2.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OVID overbought or oversold?
At the September 3, 2026 close, OVID's RSI(14) was 45.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Ovid Therapeutics Inc. holds $117.2M in cash against $12.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$33.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -26.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $1.5M (2022) to $7.3M (2025), reflecting a 383% increase over the period.
With a beta below 0.7, Ovid Therapeutics Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing OVID's risk profile alongside its fundamentals and technical indicators provides a more complete picture.